Lee Han-Soo writing for Korean Biomedical Review reports that Korean biopharma Daewoong Pharmaceutical presented tow of its new candidates at the American College of Rheumatology.  The two candidates: DWN12088:    A fibrosis treatment DWP213388:  A dual target...